LTRN Lantern Pharma Inc.
0.9100USD-4.58%Mkt Cap: 13.59M $P/E: —1d ago
Lantern Pharma Inc. focuses on the discovery and development of oncology drug in India. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small ce…
Industry Peers
Biotechnology$128.08BUSDP/E 29.4
$78.44BUSD
$76.40BUSDP/E 18.4
$57.03BUSDP/E 37.3
$58.08BUSDP/E 35.4
$42.24BUSDP/E 18.0
$43.05BUSD
$41.41BUSDP/E 65.1
$32.80BUSDP/E 30.2
$30.03BUSDP/E 37.8
$25.10BUSD
$23.93BUSD
$22.99BUSDP/E 14.5
$22.27BUSDP/E 30.7
$22.54BUSDP/E 28.9
$22.22BUSD
$15.03BUSDP/E 17.5
$15.01BUSDP/E 15.8
$14.48BUSDP/E 18.4
$14.32BUSD
| Headline | Source | Time |
|---|---|---|
Older | ||
 Lantern Pharma (LTRN) Q2 2026 Earnings Call Transcript LP-300 shows strong efficacy in lung cancer while operating losses shrink 25%. | ||
Lantern Pharma Inc (LTRN) (Q2 2026) Earnings Call Highlights: AI-Driven Pipeline Advances Amid ... Lantern Pharma reports promising LP-300 data and launches Open Medicine AI spin-out while managing a tighter cash position. | ||
Lantern Pharma Inc. Q2 2026 Earnings Call Summary Moby summary of Lantern Pharma Inc.'s Q2 2026 earnings call | ||